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Abstract
Patients with glucocorticoid (GC) excess, Cushing’s syndrome, develop a classic phenotype characterized by central obesity
and insulin resistance. GCs are known to increase the release of fatty acids from adipose, by stimulating lipolysis, however,
the impact of GCs on the processes that regulate lipid accumulation has not been explored. Intracellular levels of active GC
are dependent upon the activity of 11b-Hydroxysteroid dehydrogenase type 1 (11b-HSD1) and we have hypothesized that
11b-HSD1 activity can regulate lipid homeostasis in human adipose tissue (Chub-S7 cell line and primary cultures of human
subcutaneous (sc) and omental (om) adipocytes. Across adipocyte differentiation, lipogenesis increased whilst b-oxidation
decreased. GC treatment decreased lipogenesis but did not alter rates of b-oxidation in Chub-S7 cells, whilst insulin
increased lipogenesis in all adipocyte cell models. Low dose Dexamethasone pre-treatment (5 nM) of Chub-S7 cells
augmented the ability of insulin to stimulate lipogenesis and there was no evidence of adipose tissue insulin resistance in
primary sc cells. Both cortisol and cortisone decreased lipogenesis; selective 11b-HSD1 inhibition completely abolished
cortisone-mediated repression of lipogenesis. GCs have potent actions upon lipid homeostasis and these effects are
dependent upon interactions with insulin. These in vitro data suggest that manipulation of GC availability through selective
11b-HSD1 inhibition modifies lipid homeostasis in human adipocytes.
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Introduction
The magnitude of the obesity epidemic has heightened the
urgency to understand the mechanisms that contribute to the
regulation of adipose tissue mass. The morbidities associated with
obesity, especially central obesity, are well described and include
dyslipidaemia, insulin resistance, type 2 diabetes (T2DM),
hypertension and cardiovascular disease, all of which contribute
to increased mortality [1].
The regulation of adipose tissue mass is complex. Increases in
adipose tissue arise as a consequence of both hyperplasia (increase
in fat cell number) and hypertrophy (increase in fat cell size) [2].
Hyperplasia relies on pre-adipocyte proliferation and differentia-
tion into mature adipocytes. Adipocyte differentiation is a tightly
regulated process orchestrated by the temporal expression of key
transcription factors resulting in cyto-skeletal changes as well as the
induction of key genes involved in lipid metabolism, namely
lipogenesis, fatty acid uptake, lipolysis and b-oxidation. In mature
adipocytes the relative balance of these processes is crucial in
determining adipocyte size (and hence fat mass). Increased
lipogenesis and fatty acid uptake favour lipid accumulation within
the adipocyte, whilst lipolysis and b-oxidation promote lipid loss.
Lipogenesis occurs either as a consequence of re-esterification of
free fatty acids (FFA) with glycerol or de novo synthesis of
triacylglycerol (TAG). De novo lipogenesis may account for up to
20% of lipid turnover within adipose tissue [3]. During de novo
lipogenesis, acetyl CoA is carboxylated to malonyl-CoA by acetyl
CoA carboxylase (ACC) which is subsequently converted by a
multi-step reaction to palmitate by fatty acid synthase (FAS) [4].
There are two isoforms of ACC (ACC1 and ACC2); in lipogenic
tissues ACC1 predominates and is the key regulatory step of fatty
acid synthesis. ACC2 is localized to the mitochondrial membrane,
and its role is to limit b-oxidation through malonyl-CoA mediated
inhibition of carnitine palmitoyl transferase I (CPT I) which
catalyses the transfer of long-chain fatty acyl-CoA into the
mitochondrion. ACC1 and 2 are highly regulated at the level of
mRNA expression, protein phosphorylation and also by ubiqui-
tination and proteasomal degradation. Phosphorylation by AMP-
kinase (AMPK) at ser-79 on ACC1 and ser-218 on ACC2,
negatively regulates activity [5].
Patients with glucocorticoid (GC) excess, Cushing’s syndrome,
develop a classical phenotype characterized by insulin resistance,
proximal myopathy and central obesity. Whilst it is clear that GCs
are essential for adipocyte differentiation [6], their impact upon
many of the processes that regulate lipid accumulation within the
adipocyte have not been explored in detail. In vivo and in vitro, GCs
appear to stimulate lipolysis through a putative action upon
hormone sensitive lipase [7,8] and the resultant generation of FFA
may contribute to the development of insulin resistance [9]. This is
consistent with their role as ‘stress’ hormones, mobilizing FFA for
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b-oxidation, but a potential impact upon ACC activity and
lipogenesis and b-oxidation has not been investigated. This may be
important in explaining the clinical impact of endogenous and
exogenous GC excess.
There has been much interest in the role of endogenous GC
secretion and metabolism in the pathogenesis of human obesity.
GC availability and action depend not only upon circulating levels
but also on tissue specific intracellular activation or inactivation by
11b-hydroxysteroid dehydrogenases (11b-HSD). 11b-HSD1 is
highly expressed in adipose tissue and predominantly converts
inactive cortisone to cortisol, thus amplifying local GC action
independent of circulating cortisol concentrations [10]. Within
subcutaneous (sc) adipose tissue, there is increased 11b-HSD1
expression and activity that positively correlates with obesity and
insulin resistance [11,12]. Furthermore, studies employing 11b-
HSD1 inhibitors have demonstrated clinical efficacy in improving
insulin sensitivity in patients with type 2 diabetes [13].
Based upon the hypothesis that GC-mediated changes in lipid
homeostasis in adipose tissue are a crucial driver to the Cushing’s
phenotype, we have performed a detailed characterization of the
impact of GC on lipid flux in human adipose tissue. Furthermore
we have proposed that the action of selective 11b-HSD1 inhibitors
to improve insulin sensitivity may be in part medicated by
suppression of lipid mobilization from adipose tissue decreasing
FFA availability.
Methods
Cell Culture
Chub-S7 cell culture. The Chub-S7 cell line is a
transformed human subcutaneous pre-adipocyte cell line derived
from an obese female that has been validated as a good model of
human adipocyte biology [14,15]. Proliferating cells were cultured
in Dulbecco’s MEM/Nutrient Mixture F12, DMEM-F12 (Sigma,
Poole, UK) with 10% foetal calf serum. At confluence, cells were
differentiated for 14 days into mature adipocytes in chemically
defined media (DMEM-F12 media with Biotin 33 mM,
Pantothenate 17 mM, T3 0.2 nM, Insulin 167 nM, Cortisol
1 mM and Rosiglitazone 1 mM).
Primary subcutaneous and omental pre-adipocyte cell
culture. Paired primary human subcutaneous and omental pre-
adipocytes were obtained from ZenBio (Durham, US) and were
isolated from adipose tissue of healthy, non-diabetic donors aged
18–60 years undergoing elective surgery. Pre-adipocytes were
cultured to confluence as per the manufacturer’s guidelines using
the supplied media. Once confluent, media were changed to a
chemically defined media (ZenBio) and were differentiated into
adipocytes for 14 d.
RNA extraction and Reverse Transcription
Total RNA was extracted from cells using the Tri-Reagent
system. RNA integrity was assessed by electrophoresis on 1%
agarose gel. Concentration was determined spectrophotometrical-
ly at OD260. In a 50 ml volume 500 ng of total RNA was incubated
with 250 mM random hexamers, 500 mM dNTPs, 20 U RNase
inhibitor, 63 U Multiscribe reverse transcriptase, 5.5 mM MgCl
and 16 reaction buffer (Applied Biosystems, Foster City, CA,
USA). The reverse transcription reaction was carried out at 25uC
for 10 min, 48uC for 30 min and then the reaction was terminated
by heating to 95uC for 5 min.
Real-Time PCR
mRNA levels were determined using an ABI 7500 sequence
detection system (Perkin-Elmer Applied Biosystems, Warrington,
UK). Reactions were performed in 10 ml volumes on 96-well plates
in reaction buffer containing 26TaqMan Universal PCR Master
mix (Applied Biosystems). All primers and probes were supplied by
applied biosystems ‘assay on demand’ and reactions normalised
against the house keeping gene 18S rRNA, provided as a
preoptimized control probe. All target genes were labelled with
FAM and the housekeeping gene with VIC. The reaction
conditions were as follows: 95uC for 10-minutes, then 40 cycles
of 95uC for 15-seconds and 60uC for 1 min.
Data were obtained as ct values (ct = cycle number at which
logarithmic PCR plots cross a calculated threshold line) and used
to determine Dct values (Dct = (ct of the target gene)2(ct of the
housekeeping gene). Data were expressed as arbitrary units using
the following transformation [expression = 1000*(2
2Dct) arbitrary
units (AU)].
Protein extraction and Immunoblotting
Total protein was extracted from cells using RIPA buffer
(50 mM Tris pH 7.4, 1% NP40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF and protease
inhibitor cocktail (Roche, Lewes, UK) dissolved in 10 mL of
distilled water) and freeze thawing. Protein concentrations were
measured using a commercially available assay (Bio-Rad Labora-
tories Inc., Hercules, CA). 15 mg of protein was resolved on a
12.5% SDS PAGE gel and transferred onto nitrocellulose
membrane, Hybond ECL (GE Healthcare, Chalfont St Giles,
UK). Primary (anti-AMPK, pAMPK(Thr172), ACC1/2 and
pACC(ser79/218), (Cell Signalling Technology, Danvers, MA)
and secondary antibodies (Dako, Glostrop, UK) were used at a
dilution of 1/1000. Membranes were re-probed for b-Actin.
Primary and secondary antibodies were used at a dilution of 1/
5000 (Abcam plc, Cambridge, UK). Bands were quantified with
Genesnap by Syngene (Cambridge, UK) and expressed relative to
b-actin to normalise for gel loading.
Lipogenesis
Lipogenesis was measured by the uptake of 1-[14C]-acetate into
the lipid component as described previously [16]. At confluence or
after 14 days of differentiation Chub-S7 cells, or primary sc and
om cells were washed and cultured for 4 h in serum free media.
Cells were then incubated in 500 ml of serum free media with or
without insulin (5 nM), glucorticoids (5 or 500 nM) and the
selective 11b-HSD1 inhibitor (PF-877423, 5 mM, provided
through a material transfer agreement with Pfizer inc. (La Jolla,
CA, USA) [17]) for 18 h, 0.12 mCi/L 1-[14C]-acetic acid with cold
sodium acetate [10 mM] was added to the treatments for a further
6 h. After incubation cells were washed and scraped into 250 ml of
PBS. The lipid fraction was recovered in Folch solvent, the solvent
was evaporated and the radioactivity retained in the cellular lipid
was determined by scintillation counting and expressed as
disintegrations per minute (dpm)/per well.
b-oxidation
Rates of b-oxidation were measured by the conversion of [3H]-
palmitate to [3H]-H2O. At confluence or after 14 days of
differentiation, Chub-S7 cells were washed and cultured in serum
free media for 4 h. Cells were then incubated with 300 ul of low
glucose serum free media with 0.12 mCi/L [3H]-palmitic acid with
cold palmitate to a final concentration of 10 mM palmitate and
treated with or without insulin (5 nM) or Dex (5 or 500 nM) for
24 h. After incubation medium was recovered and precipitated
with an equal volume of 10% tricholoroacetic acid. The aqueous
component of the supernatants was extracted with 2:1 choloform
methanol solution. Radioactivity was determined by scintillation
11ß-HSD1 and Adipose Tissue Lipogenesis
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counting and expressed as disintegrations per minute (dpm)/per
well.
Fatty acid uptake
Fatty acid uptake was measured by intracellular accumulation
of [3H]-palmitate. At confluence or after 14 days of differentiation,
Chub-S7 cells were washed and cultured in serum free media for
4 h. Cells were then incubated with 300 ul of low glucose serum
free media with 0.12 mCi/L [3H]-palmitic acid with cold palmitate
to a final concentration of 10 mM palmitate and treated with or
without Dex (5 or 500 nM) for 24 h. The cells were incubated at
37uC for 24 h. After incubation cell lysate was recovered and
radioactivity was determined by scintillation counting and
expressed as disintegrations per minute (dpm)/per well.
Statistical analysis
Data are presented as mean 6 standard error. Where data were
normally distributed, t-tests (paired or unpaired where appropri-
ate) were used to compare single treatments to control. If
normality tests failed, non-parametric tests were used. ANOVA
was used to compare multiple doses and/or treatments. (SigmaStat
3.1, Systat Software, Inc. Point Richmond, CA). Statistical analysis
on real-time PCR data was performed on mean Dct values and not
fold changes.
Results
Lipid metabolism across human adipocyte differentiation
Across differentiation, mRNA expression levels of genes
involved in lipid metabolism increased significantly in Chub-S7
cells (FAS 13.6-fold p,0.01; ACC1 2.2-fold p,0.05; ACC2 4.5-
fold p,0.005). This was comparable to human cultures of primary
sc pre-adipocytes (FAS 3.6-fold p,0.05, ACC2 24.1-fold p,0.05)
although in primary sc cultures, ACC1 expression did not increase
significantly across adipocyte differentiation (table 1). mRNA
expression of AMPKa1 or AMPKa2 did not change across
differentiation in Chub-S7 or sc pre-adipocytes. Endorsing our
findings at the mRNA level, ACC1/2 protein expression increased
in Chub-S7 cells (data expressed relative to undifferentiated cells,
1.0 vs. 4.361.8, p,0.05) (figure 1a). Although AMPK mRNA
expression did not change, protein levels increased (1.0 vs.
7.261.8, p,0.001) (figure 1b).
Consistent with an increase in the expression of genes involved in
lipid metabolism 1-[14C]-acetate incorporation into lipid was higher
in differentiated Chub-S7 adipocytes compared to undifferentiated
cells (412644 vs. 53516304 dpm/well, p,0.05) (figure 1c).
Furthermore, insulin-stimulated 1-[14C]-acetate incorporation into
lipid in both undifferentiated and differentiated cells (undifferenti-
ated: 412644 vs. 662693 dpm/well, p,0.05; differentiated:
53516304 vs. 112506880 dpm/well, p,0.05) (figure 1c). In
contrast, [3H]-palmitate breakdown into water, reflecting b-
oxidation, decreased across differentiation (227058615548 vs.
101687624079 dpm/well, p,0.05). Insulin treatment did not
impact b-oxidation in either differentiated or undifferentiated cells
(undifferentiated: 227058615548 vs. 238677616261 dpm/well,
p = ns; differentiated: 101687624079 vs. 100251629916 dpm/
well, p = ns) (figure 1d).
Glucocorticoid and insulin regulation of lipid metabolism
in human adipocytes
Lipogenesis. In Chub-S7 cells high (500 nM, 24 h), but not
low (5 nM, 24 h) dose Dex, decreased ACC1 mRNA expression,
but increased expression of FAS and ACC2 (table 2a and b).
Although it did not reach significance Dex increased expression of
FAS and ACC2 in sc, but not om cells (FAS sc: 4.8762.04
(control): 10.2761.04 (5 nM, 24 h), 10.3560.97 (500 nM, 24 h)
p = ns) (ACC2 sc: 0.6760.14 (control): 1.9260.26, p =ns (5 nM,
24 h), 1.9260.06, p= ns (500 nM, 24 h)).
Whilst Dex (500 nM, 24 h) treatment increased total ACC
protein levels (3.060.4-fold, p,0.05) in Chub-S7 cells, inactivat-
ing ser-79/218 phosphorylation of ACC also increased (2.660.9-
fold, p,0.05) (figure 2a and b and figure 3b). AMPK protein
expression did not change, however phosphorylation of AMPK at
thr172 decreased following Dex treatment (figure 2c and d).
Consistent with increased ser-79/218 phosphorylation of ACC,
Dex caused a dose dependent decrease in lipogenesis (100%
(control): 70.068.2, p,0.005 (5 nM, 24 h), 56.063.9%, p,0.01
(500 nM, 24 h)), in Chub-S7 cells (figure 3a and b). These findings
were endorsed in primary cultures of differentiated sc and om pre-
adipocytes. In cells from both depots, Dex decreased lipogenesis
(sc: 81.963.9, p,0.005 (5 nM), 67.364.8%, p,0.001 (500 nM);
om: 72.065.4, p,0.005 (5 nM), 46.965.7%, p,0.01 (500 nM))
(Figure 4).
Insulin Stimulated lipogenesis
In Chub-S7 cells low dose Dex (5 nM, 24 h) significantly
enhanced the response to insulin (no insulin, no Dex (100%),
Table 1. mRNA expression levels in primary cultures of undifferentiated (day 1) and differentiated (day 14) pre-adipocytes from
Chub-S7 cells and subcutaneous pre-adipocytes tissue as measured by real-time PCR.
Chub-S7 cells Subcutaneous Pre-adipocytes
Gene Pre-adipocytes (day 1) Differentiated (day 14) p Pre-adipocytes (day 1) Differentiated (day 14) p
FABP4 0.0160.003 75.5.66.79 ,0.005 1.4660.41 37.57611.86 ,0.005
FAS 0.5760.05 7.1560.9 ,0.01 1.2360.23 6.5461.39 ,0.005
ACC1 0.3560.04 0.7960.05 ,0.05 0.2860.03 0.5460.09 ns
ACC2 0.0560.01 2.0360.14 ,0.005 0.0760.04 2.8860.74 ,0.005
AMPKa1 0.6360.07 0.4160.02 ns 0.8860.53 0.7060.24 ns
AMPKa2 0.0760.01 0.0460.004 ns 0.0560.02 0.0960.05 ns
COP1 0.5660.04 0.4860.04 ns 0.4860.12 0.2860.08 ns
TRB3 0.4160.13 0.1360.01 ns 0.9460.26 0.1660.01 ,0.05
Data are presented as arbitrary units (mean6se, n = 3–6 experiments).
doi:10.1371/journal.pone.0026223.t001
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192.5625.3 (5 nM insulin) vs. 248.3631.4%, (5 nM Dex+5 nM
insulin), p,0.05) (figure 3a). Similarly in sc cells, in the presence of
insulin (5 nM, 24 h), Dex no longer inhibited lipogenesis and did
not impair insulin-stimulated lipogenesis (no insulin, no Dex
(100%), 149.0622.1% (5 nM insulin), 145.5629.4% (5 nM
Dex+5 nM insulin) p = ns) (figure 4a). In contrast, Dex (5 nM
and 500 nM, 24 h) decreased lipogenesis in om cells in the
presence of insulin, reflecting either a persistence of the direct
action of Dex, or its ability to induce insulin resistance and limit
insulin-stimulated lipogenesis (no insulin, no Dex (100%),
208.961.9 (5 nM insulin), 181.5611.8%, (5 nM Dex+5 nM
insulin) p,0.001) (Figure 4b). In Chub-S7 cells Dex, in the
presence of insulin high dose (500 nM, 24 h), but not low (5 nM,
24 h) dose Dex, decreased ACC1 mRNA expression, but
increased expression of FAS and ACC2, complete data are
presented in table 2a and b. In the primary cells Dex in the
presence of insulin increased expression of FAS in sc, but not om,
cells although this did not reach significance (FAS sc: 3.8460.74
(5 nM insulin): 8.8160.28 (5 nM Dex+5 nM insulin, 24 h),
7.8260.65 (500 nM Dex+5 nM insulin, 24 h) p =ns). ACC2
expression increased in both sc and om cells (sc: 0.7860.07 (5 nM
insulin): 2.3560.43, p = ns (5 nM Dex+5 nM insulin, 24 h),
2.4560.04, p =ns (500 nM Dex+5 nM insulin, 24 h)), (om:
0.0860.04 (5 nM Dex+5 nM insulin, 24 h): 0.1560.04, p = ns
(5 nM, 24 h), 0.1360.03, p = ns (500 nM Dex+5 nM insulin,
24 h)) but did not reach significance.
11b-HSD1 as a regulator of lipogenesis in human adipose
tissue
We have previously demonstrated the expression of 11b-HSD1
in Chub-S7 cells and characterized its regulation across adipocytes
differentiation [17]. 24 h incubation with both cortisol and
cortisone decreased basal lipogenesis to a similar extent (100%
(control); 65.766.2 (cortisone, 500 nM) p,0.001, 50.8610.9%
(cortisol, 500 nM) p,0.005). Incubation with the selective 11b-
HSD1 inhibitor (PF-877423, 5 mM) (17) alone was without effect.
However, when co-incubated with cortisone (that requires intact
11b-HSD1 activity to generate active cortisol), cortisone-induced
repression of lipogenesis was completely abolished (100% (control);
65.766.2% (cortisone, 500 nM), 96.469.1 (cortisone 500 nM+
PF-877423 5 mM) p,0.01) (figure 5).
b-oxidation
24 h Dex treatment increased ACC2 and PDK4 mRNA
expression (ACC2: 2.860.7 (control) 4.360.9 (5 nM Dex)
p,0.05, 7.262.2 (500 nM Dex) p,0.01; PDK4: 2.560.6 (control)
Figure 1. Across Chub-S7 differentiation, total ACC (a) and AMPK (b) levels increase. Data are presented as the mean6se fold change
compared to undifferentiated cells and quantified relative to b-actin with representative western blots above (n = 3–5 experiments, * p,0.05). 1-[14C]-
acetate incorporation into lipid increased across differentiation and was stimulated by insulin in both undifferentiated pre-adipocytes and
differentiated adipocytes (c). In contrast, 3H release from 3H-palmitate decreased across differentiation and was not regulated by insulin. Data are
expressed as disintegrations per minute (dpm) and are the mean6se of n$3 experiments performed in triplicate. Basal (open bars) and insulin
stimulated (black bars) and *p,0.05.
doi:10.1371/journal.pone.0026223.g001
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Table 2. mRNA expression measured by real-time PCR of genes involved in adipocyte lipid homeostasis in differentiated Chub-S7
cells following treatment with Dexamethasone (Dex) alone (a) or in combination with insulin (b) for 24 h.
a No insulin b Insulin (5 nM)
No Dex Dex (5 nM) Dex (500 nM) No Dex Dex (5 nM) Dex (500 nM)
SDC1 362.8637.3 388.9634.7 344.9613.1 SDC1 286.5628.4 233.3629.51 224.7630.6
ACC1 2.560.5 2.460.4 1.760.8* ACC1 1.360.41 1.360.2{I 0.960.5*1
FAS 25.664.5 33.369.2* 47.467.1* FAS 15.664.6 29.566.4 39.6610.3*
DGAT1 2.460.37 2.760.4 2.560.3 DGAT1 1.560.4 1.960.4 1.860.3
GPAT 0.6960.14 0.7560.15 0.5760.13 GPAT 0.4260.10 0.5060.131 0.4960.13
COP-1 1.360.4 1.560.5 1.660.5 COP-1 1.260.3 1.260.4 1.260.3
MCD 0.6960.15 0.8760.18 0.9060.17 MCD 0.5660.20 0.5660.18 0.7660.23
CPT-1 0.7060.29 0.8160.30 0.6860.30 CPT-1 0.7960.29 0.7860.27 0.8360.25
ACC2 2.860.7 4.360.9* 7.262.2{ ACC2 3.360.9 5.361.1* 6.061.3{
FAT 81.4612.4 87.168.1 83.9611.5 FAT 63.6614.2 65.0611.41 60.5612.8
FABP4 133.1616.0 165.2613.1* 178.0616.8* FABP4 89.2613.61 123.7615.3{1 120.1616.6{1
ACS 3.361.1 3.561.0 2.060.5 ACS 1.360.5 1.260.51 0.8160.26{1
AMPKa1 0.9660.07 1.160.3 1.560.2 AMPKa1 1.360.1 1.260.2 1.460.2
PDK4 2.560.6 4.361.2 9.162.5{ PDK4 3.260.4 6.061.1 10.962.0{
Data are presented as arbitrary units6standard error and are the mean of n = 5–7 experiments (* p,0.05, { p,0.01, { p,0.005 vs. no Dex; 1 p,0.05, I p,0.005 vs. no
insulin at same concentration of Dex).
doi:10.1371/journal.pone.0026223.t002
Figure 2. Dexamethasone (Dex, 500 nM, 24 h) increases both total ACC levels (a) and ser-79/218 phosphorylation of ACC (b) in
differentiated Chub-S7 cells. Total AMPK levels are not changed (c), but Thr172 phosphorylation is decreased (d). Data are presented as the
mean6se fold change compared to untreated cells and quantified relative to b-actin with representative western blots above (n = 3–5 experiments,
control open bars, Dex black bars, * p,0.05).
doi:10.1371/journal.pone.0026223.g002
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4.361.2 (5 nM Dex) p= ns, 9.162.5 (500 nM Dex) p,0.005)
(Table 1a). Dex and insulin treatment, both alone and in
combination did not alter b-oxidation, as measured by the
conversion of [3H]-palmitate to [3H]-H2O, in differentiated
Chub-S7 cells. (100% (control); 102.360.6% (5 nM Dex),
104.865.5% (500 nM Dex), 105.862.2 (5 nM insulin),
102.662.6% (5 nM Dex+5 nM insulin), 103.762.1% (500 nM
Dex+5 nM insulin)
Fatty acid uptake
In differentiated Chub-S7 cells both low (5 nM, 24 h) and high
(500 nM, 24 h) dose Dex increased FABP4 expression (table 1a)
and in the absence of insulin increased [3H]-palmitate uptake
(100% (control); 118.265.1% (5 nM Dex), 127.466.1% (500 nM
Dex) p,0.05).
Depot Specific Differences
Sc pre-adipocytes differentiated to a greater degree than om
pre-adipocytes, with higher mRNA expression of lipid metabolism
genes (ACC1 3.2-fold, FAS 10.9-fold, ACC2 17.8-fold, LPL 44.7-
fold) and higher 1-[14C]-acetate incorporation into lipid compared
to om cells (3.8-fold, 5646117 vs. 21546222 dpm/well,
p,0.005). However, lipogenesis in om cells was more responsive
to insulin stimulation (100% (control): sc 149622.14%, om
20961.86%, p= 0.05) (Figure 4a and b).
Discussion
The actions of GCs upon adipose tissue are complex, but they
are essential for adipocyte differentiation [6]. In this paper, we
have performed a detailed characterization of lipid homeostasis in
the human pre-adipocyte cell line Chub-S7. Across differentiation,
total ACC protein levels increased, although, we were unable to
distinguish ACC1 and 2 (due to lack of suitable antibodies) the net
effect would be to promote lipid accumulation. Increased ACC1
drives lipogenesis, whilst increased ACC2 will limit b-oxidation
and it is this pattern of dynamic lipid flux that we observed across
adipocyte differentiation. Consistent with published data [18],
insulin was able to stimulate lipogenesis in both undifferentiated
and differentiated cells as well as in primary sc and om cultures but
failed to regulate b-oxidation. Whilst for the most part the data
from the Chub-S7 cell line matched very well with data from
primary cultures, it is possible that the transformations used to
generate the Chub-S7 cell line could potentially have modified
their behaviour and characteristics.
In mature adipocytes, GCs stimulate FFA uptake, via lipopro-
tein lipase activity, as well as driving lipolysis though hormone
sensitive lipase [8,19] and AGTL [20]. In addition, we have
previously shown that limiting GC exposure to adipose tissue in
vivo decreases lipolysis [21]. Dietary TAG is the main source of
lipid stored within adipocytes, however, over feeding studies in
humans suggest 40% of increases in fat mass are due to de novo
lipogenesis [22]. In rodent models, GCs inhibit insulin-stimulated
de novo lipogenesis by decreasing FAS and ACC activity [23,24]. In
the only human study published to date, GC action in isolation
was not examined. GCs and insulin, (when compared to insulin
alone), increased FAS activity and lipogenesis in sc adipocytes, as
measured by glucose incorporation into cellular lipids [25]. In our
study, GCs increased ACC2 (but not ACC1) and FAS mRNA
expression as well as total ACC protein levels (which may reflect
Figure 3. In the absence of insulin, dexamethasone (Dex) decreases lipogenesis as measured by 1-[14C]-acetate incorporation into
lipid in differentiated Chub-S7 cells in a dose dependent manner (a) and is associated with increasing ser79/218 phosphorylation
of ACC (b). Insulin stimulates lipogenesis and the actions of insulin are augmented in the presence of low dose (5 nM), but not high dose (500 nM)
Dex (a), where Dex is only able to increase phosphorylation at the higher dose. Control cells are shown in the white bars, low dose dexamethasone
treatment (5 nM) grey bars, high dose (500 nM) black bars, * p,0.05) representative western blot is shown.
doi:10.1371/journal.pone.0026223.g003
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ACC2) but decreased functional lipogenesis in all adipocyte cell
models.
Global deletion of ACC1 in rodents results in embryonic
lethality [26], but targeted liver-specific deletion, decreases
lipogenesis and lipid accumulation without alteration in b-
oxidation or glucose homeostasis [27]. In contrast, ACC2
knockout mice have unaltered adipocyte malonyl CoA levels
[28] suggesting that it is not involved in lipogenesis. The changes
that we have observed in 1-[14C]-acetate incorporation into lipid
are therefore most likely to reflect regulation of specific ACC1
activity. ACC 1 and 2 are negatively regulated by phosphorylation
at Ser-79 and 218 respectively by AMPK [5]. We observed an
increase in serine phosphorylation of ACC following GC
treatment and this translated to a net decrease in lipogenesis.
However, in contrast to observations in hepatocytes where GCs
increase AMPK expression [29] this was unchanged in Chub-S7
cells, sc and om human primary cultures (data not shown).
Furthermore, activating phosphorylation of AMPK at Thr172 was
decreased by GC treatment suggesting that regulation of ACC1
through serine phosphorylation is likely to be independent of
AMPK in human adipose tissue. Our data are in agreement with
studies on adipocytes differentiated from mesenchymal stem cells
where Dex did not alter gene or protein expression, but decreased
AMPK activity [30] and with obervations in adipose tissue fom
patients with Cushing’s syndrome, where AMPK phosporylation is
decreased [31].
In Chub-S7 cells, Dex augmented insulin-stimulated lipogenesis
and this is in agreement with our previous studies [14] as well as
others [32] that have shown enhanced activation of the insulin
signalling cascade and glucose uptake following pre-treatment of
adipocytes with GC. In sc and om cells in this study, the
incremental response to insulin stimulation was similar with and
without low dose Dex and suggests that this dose (5 nM) is not
sufficient to cause insulin resistance. At the highest dose (500 nM)
in om, but not sc cells, Dex in combination with insulin decreased
lipogenesis. Although these changes were not matched by the
expected pattern of changes in mRNA expression, it is possible
that this may reflect the complex post-translational regulation of
lipogenesis and it is entirely plausible that there may exist a depot-
specificity of regulation. In addition, extrapolating these observa-
tions to the in vivo situation is complex and represents a balance of
‘direct’ GC actions to decrease lipogenesis as well as any potential
action to cause insulin resistance and abrogate the effect of insulin
treatment.
These observations do raise the intriguing possibility of
differential nutritional regulation of lipogenesis. In the fasting
state, low insulin levels and high endogenous GC levels will
stimulate lipolysis and simultaneously switch off lipogenesis though
serine phosphorylation of ACC1, decreasing fuel storage and
increasing FFA availability for other more metabolically active
tissues. Conversely, in the fed state, insulin levels are high, and
here insulin and GC may act together to promote lipid storage.
However, we must exert a note of caution as extrapolating from in
vitro models to in vivo observations is fraught with difficulty and
these hypotheses will need to be tested in dedicated, well designed
clinical studies.
Whilst obesity per se is detrimental to health, regional
distribution of adipose tissue is crucially important. Intra-
abdominal, as opposed to sc adipose deposition, correlates with
insulin resistance [33] and increased cardiovascular morbidity and
mortality [34]. The molecular mechanisms that underpin depot
specific differences in fat accumulation are therefore of great
interest. This study used differentiated pre-adipocytes from paired
sc and om depots and as sc cell in culture differentiate to a greater
degree comparisons of hormone responsiveness between cell types
is difficult. Differences in insulin action between adipose tissue
depots have been described [35–38]. Interestingly, despite a lower
level of differentiation, lipogenesis in om cells responded more
dramatically to insulin treatment, however, a dedicated study in a
more suitable model is required.
GC availability and action not only depend upon circulating
levels, but also on the tissue specific intracellular activation or
inactivation by 11b-HSD. In vitro, rodent and clinical data have
endorsed 11b-HSD1 as a metabolic therapeutic target [39–41]
and inhibitor studies including phase II studies in man are now
published [13]. Improvements in lipid profiles as well as insulin
sensitivity have been demonstrated for a number of compounds,
but the precise mechanisms by which they convey their metabolic
benefit remains to be confirmed. In skeletal muscle, selective 11b-
HSD1 inhibitors alter lipid metabolism decreasing FFA availabil-
ity [42] and this may underpin their ability to cause insulin
sensitization through a putative impact to limit protein kinase C
activation [43]. In adipose tissue we have previously demonstrated
that 11b-HSD1 inhibition decreases lipolysis [21] and have now
shown that these compounds can enhance lipogenesis. Taken
together, these observations suggest that decreased lipid mobiliza-
tion may represent a potential mechanism by which these
compounds improve metabolic phenotype.
Figure 4. In primary cultures of differentiated subcutaneous (a)
and omental (b) pre-adipocytes, Dex decreases lipogenesis in
the absence of insulin. Insulin stimulates lipogenesis in both
subcutaneous and omental cells (a and b). In omental cells only, Dex
impairs the ability of insulin to stimulate lipogenesis (b). (Activity data
are expressed relative to untreated cells (no insulin, no Dex) and are the
mean6se of n = 3–5 experiments. Control cells are shown in the white
bars, low dose dexamethasone treatment (5 nM) grey bars, high dose
(500 nM) black bars, * p,0.05 vs. Ctrl and 1 p,0.05 om, 5 nM insulin vs.
sc, 5 nM insulin).
doi:10.1371/journal.pone.0026223.g004
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In conclusion, we have demonstrated that GCs have potent
actions upon lipid homeostasis and also interact with insulin in
human adipocyte cell lines and primary cultures. Manipulation of
GC availability through selective 11b-HSD1 inhibition has
therapeutic potential by altering lipid homeostasis in key metabolic
target tissues and this may underpin their putative action as insulin
sensitizers.
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